Want to join the conversation?
$CELG cuts 2015 EPS guidance to $2.02-2.24 from prior estimate of $2.17-2.46, while affirming its adjusted EPS outlook of $4.75-4.85 and net product sales forecast of $9-9.5Bil. $CELG lifts 2015 Revlimid sales outlook to about $5.8Bil from $5.6-5.7Bil, while cutting Abraxane sales guidance to $0.95-1Bil from $1-1.25Bil.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?